. . . . . . . . . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)"@en . . . "\u056F\u056C\u056B\u0576\u056B\u056F\u0561\u056F\u0561\u0576 \u0583\u0578\u0580\u0571\u0561\u0580\u056F\u0578\u0582\u0574"@hy . . "An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)"@en . . . . . . . "klinisch onderzoek"@nl . . . . . . . . . . . . . . . . . . . . . . . "18"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)"@en . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . . . . . . "An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)"@en . "1160"^^ . . . . . . . "80"^^ . . . . . . . . . "2018-06-18T00:00:00Z"^^ . . . . . . . . . . . . "2020-09-07T00:00:00Z"^^ . . . . . . . "NCT03518086" . . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .